ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses.

H. Tedesco-Silva, C. Felipe, A. Brigido, M. Cristelli, M. Paula, A. Bessa, P. Ruppel, J. Medina-Pestana.

Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.

Meeting: 2016 American Transplant Congress

Abstract number: C80

Keywords: Cytomeglovirus, Economics, Immunosuppression, Kidney transplantation

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Economics, Public Policy, Allocation, Ethics

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus
  • Cost Effectiveness of a Belatacept-Based Regimen in Kidney Transplant Recipients

A cost-effectiveness analysis was performed using data from a prospective single center trial where de novo kidney transplant recipients received a single 3 mg/kg dose of rabbit antithymocyte globulin, tacrolimus, everolimus and prednisone (r-ATG/EVR, n=85); basiliximab, tacrolimus, everolimus and prednisone (BAS/EVR, n=102) or basiliximab, tacrolimus, mycophenolate and prednisone (BAS/MPS, n=101). This analysis was developed from the perspective of the Public Healthcare System. The clinical outcomes considered for this analysis were: acute rejection, CMV viremia/disease, graft dysfunction, surgery complications, graft loss and death. The economic outcomes contemplated in the analyses were direct medical costs, including: immunosuppression, treatment of adverse events and follow-up of patients. To estimate costs and outcomes for each treatment a Markov model was used to follow patients during 12 months after transplantation.

Compared to the standard of care regimen, r-ATG/EVR and BAS/EVR were associated with 36% and 15% reduction in costs. This was primarily due to lower costs associated with the management of adverse events as there were no significant differences in the costs of immunosuppressive drugs. Compared to the standard of care regimen, r-ATG/EVR showed higher effectiveness in all clinical outcomes while BAS/EVR showed higher effectiveness for the prevention of CMV infection and graft loss and comparable effectiveness for the other clinical outcomes. A probabilistic sensitive analysis with 1000 simulations, using ±20% variation in costs and beta distributions for transition probabilities, efficacy and safety data, confirmed these observations.

Conclusion: In this cohort of de novo kidney transplant recipients receiving tacrolimus and prednisone and no CMV pharmacological prophylaxis, everolimus containing regimens were dominant (cost-effective) compared to the standard of care regimen.

CITATION INFORMATION: Tedesco-Silva H, Felipe C, Brigido A, Cristelli M, Paula M, Bessa A, Ruppel P, Medina-Pestana J. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tedesco-Silva H, Felipe C, Brigido A, Cristelli M, Paula M, Bessa A, Ruppel P, Medina-Pestana J. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/reduced-incidence-of-cytomegalovirus-infection-in-kidney-transplant-recipients-receiving-everolimus-a-cost-effectiveness-analyses/. Accessed February 25, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.